PMID- 35498428
OWN - NLM
STAT- MEDLINE
DCOM- 20220503
LR  - 20221207
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Factors Defining the Association Between Vitamin D and Testosterone in Males With 
      Type 2 Diabetes and Hypogonadism.
PG  - 842722
LID - 10.3389/fendo.2022.842722 [doi]
LID - 842722
AB  - OBJECTIVE: This study aimed to evaluate Serum 25-hydroxyvitamin D (25[OH]D) 
      levels in diabetic men with and without hypogonadism and figured out the 
      potential factors influencing the connection between vitamin D and testosterone. 
      METHODS: A total of 367 men with type 2 diabetes mellitus (T2DM) were 
      investigated, including 254 men with normal gonadal function (Group 1) and 113 
      men with hypogonadism (Group 2). Men with hypogonadism were classified as either 
      hypogonadotropic hypogonadism (Group 2a) or hypergonadotropic hypogonadism (Group 
      2b). Serum 25(OH)D levels were detected by liquid chromatography-tandem mass 
      spectrometry in all cases. Morning total testosterone (TT), estradiol (E), 
      dehydroepiandrosterone (DHEA), prolactin (PRL), sex hormone-binding globulin 
      (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid 
      function, parathyroid and adrenal hormones, fasting blood glucose (FBG), fasting 
      insulin (Fins) and hemoglobin A1c (HbA1c) were also assessed. RESULTS: The 
      prevalence of hypovitaminosis D in men with T2DM was up to 96.46%. Serum 25(OH)D 
      levels were significantly lower in men with hypogonadism than those with 
      eugonadism (16.65 +/- 6.44 ng/mL vs. 18.17 +/- 6.17 ng/mL, P=0.033). The lowest 
      25(OH)D level was observed in Group 2a (16.22 +/- 6.52 ng/mL). After adjustment for 
      the selected factors, serum 25(OH)D concentrations were shown to be positively 
      correlated with TT concentrations (r=0.137, P=0.032). The relationship between 
      25(OH)D and testosterone was altered by age, duration of T2DM, body mass index, 
      and HbA1c. Serum 25(OH)D level was positively associated with serum TT level in 
      men with age <60 years (r=0.180, P=0.003), or with duration>/=5 years (r=0.186, 
      P=0.013), or with body mass index (BMI)>/=28kg/m(2) (r=0.431, P=0.000), or with 
      HbA1c>/=9% (r=0.145, P=0.031). CONCLUSIONS: These findings indicate that type 2 
      diabetes patients with hypogonadism have lower 25(OH)D levels than those without 
      hypogonadism. There seems to be a positive association between the serum 25(OH)D 
      and TT levels, which affected by age, duration, BMI, and HbA1c.
CI  - Copyright (c) 2022 Hu, Han, Chen, Xiang, Wei, Gong, He, Su, Chen and Liu.
FAU - Hu, Xin
AU  - Hu X
AD  - Endocrine and Diabetes Center, Affiliated Hospital of Integrated Traditional 
      Chinese and Western Medicine, Jiangsu Province Academy of Traditional Chinese 
      Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
FAU - Han, Xue
AU  - Han X
AD  - Endocrine and Diabetes Center, Affiliated Hospital of Integrated Traditional 
      Chinese and Western Medicine, Jiangsu Province Academy of Traditional Chinese 
      Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
FAU - Chen, Yu
AU  - Chen Y
AD  - Key Laboratory of Tradicional Chinese Medicine Syndrome and Treatment of Yingbing 
      of State Administration of Traditional Chinese Medicine, Jiangsu Province Academy 
      of Traditional Chinese Medicine, Nanjing, China.
FAU - Xiang, Pingping
AU  - Xiang P
AD  - Endocrine and Diabetes Center, Affiliated Hospital of Integrated Traditional 
      Chinese and Western Medicine, Jiangsu Province Academy of Traditional Chinese 
      Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
FAU - Wei, Xiao
AU  - Wei X
AD  - Key Laboratory of Tradicional Chinese Medicine Syndrome and Treatment of Yingbing 
      of State Administration of Traditional Chinese Medicine, Jiangsu Province Academy 
      of Traditional Chinese Medicine, Nanjing, China.
FAU - Gong, Tong
AU  - Gong T
AD  - Endocrine and Diabetes Center, Affiliated Hospital of Integrated Traditional 
      Chinese and Western Medicine, Jiangsu Province Academy of Traditional Chinese 
      Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
FAU - He, Zhiwei
AU  - He Z
AD  - Endocrine and Diabetes Center, Affiliated Hospital of Integrated Traditional 
      Chinese and Western Medicine, Jiangsu Province Academy of Traditional Chinese 
      Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
FAU - Su, Yafeng
AU  - Su Y
AD  - Endocrine and Diabetes Center, Affiliated Hospital of Integrated Traditional 
      Chinese and Western Medicine, Jiangsu Province Academy of Traditional Chinese 
      Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
FAU - Chen, Guofang
AU  - Chen G
AD  - Endocrine and Diabetes Center, Affiliated Hospital of Integrated Traditional 
      Chinese and Western Medicine, Jiangsu Province Academy of Traditional Chinese 
      Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
FAU - Liu, Chao
AU  - Liu C
AD  - Endocrine and Diabetes Center, Affiliated Hospital of Integrated Traditional 
      Chinese and Western Medicine, Jiangsu Province Academy of Traditional Chinese 
      Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20220412
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Vitamins)
RN  - 1406-16-2 (Vitamin D)
RN  - 3XMK78S47O (Testosterone)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Female
MH  - Glycated Hemoglobin
MH  - Humans
MH  - *Hypogonadism/complications
MH  - Male
MH  - Middle Aged
MH  - Testosterone
MH  - Vitamin D
MH  - Vitamins
PMC - PMC9039328
OTO - NOTNLM
OT  - hypogonadism
OT  - males
OT  - testosterone
OT  - type 2 diabetes
OT  - vitamin D
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/05/03 06:00
MHDA- 2022/05/04 06:00
PMCR- 2022/01/01
CRDT- 2022/05/02 07:11
PHST- 2021/12/24 00:00 [received]
PHST- 2022/02/14 00:00 [accepted]
PHST- 2022/05/02 07:11 [entrez]
PHST- 2022/05/03 06:00 [pubmed]
PHST- 2022/05/04 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.842722 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Apr 12;13:842722. doi: 
      10.3389/fendo.2022.842722. eCollection 2022.